LYCOS RETRIEVER 
Rheumatoid Arthritis: Studies
built 271 days ago
In February 2006, the Company completed enrollment in a Phase IIa study in RA patients designed to demonstrate proof of concept that TRU-015 measurably improves the signs and symptoms of rheumatoid arthritis. In the first 24 weeks after receiving intravenous infusions of TRU-015, 72 percent of the subjects experienced a clinical response that is equal to or greater than that required to achieve an ACR20 response, 28 percent achieved an ACR50 response and 14 percent achieved an ACR70 response. In these measures of clinical response, ACR 50 and ACR70 indicate progressively greater responses from a baseline measure than ACR20, which is defined as an improvement of at least 20 percent from baseline in counts of both tender and swollen joints, as well as in at least three of five other disease activity parameters.
Source:
New data supports IL-6 receptor inhibition as a key component in controlling inflammation from RARoche today announced significant results from 'OPTION'1, the first rheumatoid arthritis multinational phase III study of Actemra (tocilizumab) outside of Japan. [click link for full article] ...more
Source:
"Identifying this risk gene is important because it points us in the right direction," said Dr. Gregersen, who ... just completed a whole genome-wide association study of rheumatoid arthritis that will appear later this month in the NEJM. The study is online as of September 6th with an accompanying editorial. In this paper, the scientists identified another risk gene -- TRAF1-C5.
Source:
Cardiovascular deaths accounted for about half of the deaths for rheumatoid arthritis patients in the research sample. The findings did not distinguish between the types of cardiovascular disease that led to mortality. An earlier Mayo study confirmed a strong link between rheumatoid arthritis and congestive heart failure....
Source:
On Sept. 10, 2007, Trubion announced preliminary analysis of results for its TRU-015 Phase IIb randomized, double-blind, placebo-controlled, multicenter clinical trial that included 276 patients with rheumatoid arthritis. Patients were randomized equally into five groups that received either placebo, 200 mg, 400 mg, 800 mg or 1,600 mg of TRU-015. The study was designed to evaluate the safety and efficacy of a single intravenous infusion of TRU-015 compared to placebo for a 24-week period.
Source:
NEW YORK (Reuters Health) - Patients in the early stages of rheumatoid arthritis may have less joint damage if they take the steroid drug prednisone, according to the results of a study conducted in the Netherlands. However, long-term use of the drug--even at relatively low doses--appears to increase the risk of bone fractures, experts warn.
Source:
MORE ABOUT
Studies